High Risk Myelodysplasia clinical trials at UC Irvine
1 research study open to new patients
open to eligible people ages 18 years and up
This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.
Orange, California and other locations